Blog

Bloomberg Interviews Michael Wynne on Bristol Myers Deferred Adjudication

Bristol-Myers Squibb Company is an American pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

The company was involved in an accounting scandal in 2002 that resulted in a significant restatement of revenues from 1999 to 2001.

The company entered into deferred adjudication with the U.S. Department of Justice and Securities and Exchange Commission, agreeing to pay $150 million while neither admitting nor denying guilt.

Bloomberg interviewed former U.S. Attorney Michael J. Wynne in 2006 regarding the Bristol Myers deferred adjudication.

Recent blog posts

Joseph Larsen Gives HBA Presentation: Sovereign Immunity, Declaratory Judgements and Open Government

“Long term and recent decisions of the Texas Supreme Court have applied the doctrine of sovereign immunity to all but eliminate use of a petition for declaratory judgment to enforce compliance by governmental bodies with...

Read More +

Fifth Circuit Clarifies “Proximity” as a Factor in Imputing “Willfulness” — A Potential Breakthrough for Defense in Federal Health Care Fraud Prosecutions

By: Jim Turner, Attorney, Gregor Wynne Arney, PLLC United States v. Nora, Case No. 18-3178, 2012 WL 716628 (5th Cir. 02/24/2021) Home health care operations are often small businesses with an administrative office out of which...

Read More +

Is Embezzlement a Felony?

Understanding Felony Embezzlement, the Consequences of Embezzlement and What to Do If You Are Accused There are often news reports about a manager of a well-known person who bilked well-known clients out of large amounts...

Read More +

Contact Us

Get powerful legal representation. Contact Michael J. Wynne to begin your defense now.

123